Update: Adverse events associated with anthrax prophylaxis among postal employees - New Jersey, New York City, and the District of Columbia Metropolitan Area, 2001

Morbidity and Mortality Weekly Report

Volumn 50, Issue 47, 2001, Pages 1051-1054

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; DOXYCYCLINE;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SKIN DISEASE; BACTERIAL SPORE; BIOLOGICAL WARFARE; HUMAN; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; POSTAL MAIL; RESPIRATORY TRACT INFECTION; UNITED STATES;

ANTHRAX; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACILLUS ANTHRACIS; BIOTERRORISM; CIPROFLOXACIN; DISTRICT OF COLUMBIA; DOXYCYCLINE; HUMANS; NEW JERSEY; NEW YORK CITY; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; POSTAL SERVICE; RESPIRATORY TRACT INFECTIONS; SKIN DISEASES, BACTERIAL; SPORES, BACTERIAL;

EID: 0035977303     PISSN: 01492195     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. CDC. Update: investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR 2001;50:889-93.
2. CDC. Update: investigation of bioterrorist-related anthrax and adverse events from antimicrobial prophylaxis. MMWR 2001;50:973-6.
3. Segev S, Yaniv I, Haverstock D, Reinhart M. Safety of long-term therapy with ciprofloxacin: data of controlled clinical trials and review. Clin Infect Dis 1999;28:229-308.
4. Food and Drug Administration. Medical review. Available at 〈http://www.fda.gov/cder/foi /nda/2000/19-537S038_cipro.htm〉. Accessed November 2001.
5. Halkin H. Adverse effects of the fluoroquinolones. Rev Infect Dis 1988;10(suppl 1 ):S258-S261.